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refacearolaner—a  novel  isoxazoline—addresses  the  need  for  enhanced  ﬂea
nd  tick  controlThis Special Edition is dedicated to describing data on the dis-
overy, spectrum of efﬁcacy, and unique properties of sarolaner,
 novel isoxazoline speciﬁcally designed to meet the challenges
hat ﬂeas and ticks present for pets. Fleas and ticks are not merely
 nuisance for pet owners—these arthropod vectors threaten the
ealth of both pets and people and transmit potentially fatal disease
gents, several of which pose severe public health consequences.
n the past few decades, veterinarians have witnessed a dramatic
ransformation in products that allow safe and effective control
f ﬂeas and ticks on pets. The isoxazolines, which provide persis-
ent treatment for ﬂeas, ticks, and mites in an oral formulation,
epresent the most recent examples of this dramatic evolution in
ffective ectoparasiticides.
In recent years, an increasing number of ﬂea and tick-borne
athogenic organisms have been identiﬁed globally and the
iomedical importance of ﬂea and tick-transmitted infectious dis-
ases has been recognized. The ongoing and expanding Lyme
isease epidemic in the northern hemisphere, urbanization of
ick habitat, the rapid increase in deer and other wildlife pop-
lations within the peri-domestic environment, the recognition
hat the same tick-borne pathogens can cause disease in pets and
heir owners, and the widespread availability of safe and effective
caracides have all contributed to enhance the awareness of tick-
orne infections among medical professionals and pet owners. The
et and the owner are both at risk of acquiring these infections
rom vectors in the environment. Some tick-borne organisms are
ighly pathogenic, such as Rickettsia rickettsii, the causative agent
f potentially fatal Rocky Mountain spotted fever in the Americas.
ther arthropod-borne organisms, including babesiosis, bartonel-
osis and ehrlichiosis, cause persistent infections and resultant
omplex disease expression that can mimic  autoimmune, immune-
ediated or neoplastic diseases. There has also been the concurrent
iscovery of a variety of new tick-borne organisms for which clin-
cal, epidemiological and pathological data is minimal or lacking,
articularly in regard to disease causation in pets.
A one health approach to ﬂea and tick-borne disease preven-
ion is of critical importance. This concept emphasizes the need to
ntegrate animal health, human health and environmental factors,
hile coordinating research priorities designed to enhance diag-
osis, treatment and prevention of these vector-borne infections
mong pets and people. A better understanding of the interac-
ions of people, vectors, animals and the environment will allow
or improvements in knowledge of the myriad of disease man-
ttp://dx.doi.org/10.1016/j.vetpar.2016.02.033
304-4017/© 2016 Published by Elsevier B.V. This is an open access article under the CC Bifestations and clinical presentations, collectively known as ﬂea
and tick-borne diseases. Physicians, veterinarians and other animal
health professionals should be educated as to the large number of
ﬂea and tick-borne pathogens in nature, the spectrum of animal
reservoir hosts, the diversity of conﬁrmed and potential arthro-
pod vectors, current limitations associated with diagnosis and
establishing effective treatments, and the ecological and evolving
medical complexity associated with these pathogens. It is critical
for physicians and veterinarians to consider each patient’s travel
history, exposures to domestic animals and wildlife, exposure to
arthropod vectors, and potentially whether there is a history of
blood product administration.
Transmission of disease agents varies depending on the arthro-
pod vector/pathogen system considered. Most pathogens are
transmitted by the blood feeding activity of the arthropods, but
some may  be passed in frass (e.g., Bartonella henselae) while others
required the vertebrate to ingest the tick or tissues of a paratenic
host (e.g., Hepatozoon spp.). Pathogens transmitted by blood feed-
ing may  transmit within a few hours of attachment (e.g., Rickettsia
spp., Ehrlichia spp.), after 24–48 h of attachment (e.g., Borrelia
burgdorferi sensu stricto), or after 2–3 days or more of tick feeding
(Babesia spp.). Longer feeding by the tick usually facilitates more
efﬁcient transmission. As systemic insecticide/acaricides, the abil-
ity of isoxazolines to prevent transmission of infection by blood
feeding arthropods likely relies upon how rapidly they disrupt feed-
ing and kill the vector. Research in this special issue and published
elsewhere documents that the isoxazlines are able to limit the dura-
tion of tick feeding and may  reduce transmission of some infections.
Sarolaner was discovered by Zoetis scientists through a tar-
geted synthesis and screening program that evaluated over 3000
individual compounds and was  selected for development on the
basis of structural uniqueness, potency, mammalian safety, and
pharmaco-kinetic suitability to deliver a month long efﬁcacy pro-
ﬁle. Sarolaner (2–4 mg/kg) formulated in a ﬂavored, chewable
tablet (SimparicaTM) was  effective for the treatment and persis-
tent control of ﬂeas and ticks for at least one month and for the
treatment of Otodectes ear mites and Sarcoptes and Demodex mange
mites. Against the cat ﬂea, Ctenocephalides felis, sarolaner provided
rapid onset of activity with ≥98% control within eight hours of treat-
ment or subsequent re-infestations for 28 days. This consistent and
rapid efﬁcacy resulted in the complete cessation of ﬂea egg laying
for 35 days and in a simulated ﬂea-infested, home environment
study, ﬂea counts were reduced by 96% within two weeks and ﬂeas
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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liminated from dogs after the second monthly dose. A month’s
rotection was also conﬁrmed against the dog ﬂea (Ctenocephalides
anis). Studies with four US ticks (Amblyomma americanum, Ambly-
mma maculatum, Dermacentor variabilis, Ixodes scapularis),  three
uropean ticks (Dermacentor reticulatus,  Ixodes hexagonus,  Ixodes
icinus)  and the globally distributed tick (Rhipicephalus sanguineus)
howed >99% efﬁcacy within 48 h of dosing against existing infes-
ations and >95% efﬁcacy by 48 h after weekly re-infestations for
t least 35 days. Sarolaner’s speed of kill of ticks was evaluated
gainst A. maculatum, I. ricinus and I. scapularis,  >90% efﬁcacy was
chieved within 12 h and 100% by 24 h after dosing and efﬁcacy of
89.6% was attained by 24 h after re-infestation for at least 28 days.
arolaner was shown to effectively prevent the transmission of B.
urgdorferi and Anaplasma phagocytophilum from infected ticks to
ogs treated four weeks previously. Field studies conducted in the
S and Europe demonstrated the safety of three monthly treat-
ents with sarolaner in over 600 client-owned dogs. Field efﬁcacy
f sarolaner was >98% against ﬂeas and >97% against ticks at all
ost-treatment evaluations. In addition the SimparicaTM chewable
ablets were highly palatable with tablets readily consumed by dogs
n 93% of the 1280 occasions they were offered by free choice in
he European ﬁeld studies.logy 222 (2016) 1–2
SimparicaTM chewable tablets containing sarolaner provide
rapid treatment and consistent month-long control of both ﬂeas,
and the main tick species, affecting dogs in the US and Europe
following oral dosing. Its rapid onset of efﬁcacy and speed of kill
throughout the entire month is important as the quick interrup-
tion of feeding by these parasites is critical to ameliorate the direct
adverse and irritant effects of feeding and to also reduce the risk of
transmission of vector-borne pathogens.
Guest Editor
Dr. Ed Breitschwerdt
Guest Editor
Dr. Susan Little
Guest Editor
Dr. Douglas Rugg ∗
